All posts related to "patients"

Patient-Centred Care: training the next generation of health-care providers

Over the last decade, patient-centred care (PCC) has become a focus within rheumatology and in the broader healthcare community. Patient-centred care puts patients and their families at the forefront of the care that they receive. According to the British Columbia Patient-Centred Care Framework, patient-centred care incorporates the following key components:

  • Self-management;
  • Shared and informed decision-making;
  • An enhanced experience of health care;
  • Improved information and understand; and,
  • The advancement of prevention and health promotion activities.

This approach emphasizes patient-voice, information sharing and shared decision making – ensuring there is a collaboration between the patient, their family, and their health care provider(s). There should be a balance between the health professional’s knowledge and the patient’s personal knowledge, experiences and preferences. PCC is based around team work rather than a potentially unbalanced healthcare provider-patient relationship. PCC has been shown to increase patient satisfaction, improve self-management, and ultimately lead to better health outcomes. Health authorities, patient advocate groups, and researchers throughout Canada are working to make patient centred care a priority.

There are several challenges to delivering PCC on a systemic level. It requires a significant shift to the way in which the healthcare system operates, and perhaps more importantly, a significant shift in the culture of health care. An effective way of transitioning to PCC is to ensure that the next generation of health professionals have sufficient training in the area. An effective way to achieve this is to have students learn directly from patient advocates and patient educators. In October, the Pharmacy School at the University of British Columbia (UBC) led by example by doing exactly that.

Continue reading

ACR News 3 – October 23, 2018

newspaper in mail slotACE is reporting from this week’s American College of Rheumatology/Association of Rheumatology Health Professionals 2018 Annual Meeting. Here are some presentations that are important for arthritis patients.

The future of arthritis care and the next generation of arthritis specialists 

The Arthritis Alliance of Canada has looked carefully at how patients with arthritis receive timely diagnosis and treatment. Central to ensuring timely care is making sure there are adequate numbers of rheumatologists for making an early diagnosis and starting appropriate treatment. In 2015, the Canadian Rheumatology Association conducted a national workforce survey of rheumatologists across Canada. The survey found there is a current shortage of rheumatologists across the country that may worsen over the next 10 years because a third of the workforce reported plans to retire in the near future. This will occur at the same time as an expected increase in the number of arthritis patients within the next generation.
Continue reading

ACR News 2 – October 22, 2018

newspaper in mail slotACE is attending this week’s American College of Rheumatology/Association of Rheumatology Health Professionals 2018 Annual Meeting, the largest international gathering of arthritis researchers, clinicians, academics, patient advocates and arthritis health professionals. Here are some of today’s highlights:

Improving osteoarthritis management

There are currently more than 4.4 million Canadians living with osteoarthritis (OA). Within a generation (in 30 years), more than 10 million (or one in four) Canadians are expected to have OA. A 2017 study, “Productivity costs of work loss associated with osteoarthritis in Canada from 2010 to 2013,” found the rising rates of OA will cost the Canadian economy an estimated $17.5 billion a year in lost productivity by 2031 as the disease forces greater numbers of people to stop working or work less.

ACE and other members of the Arthritis Alliance of Canada have helped raise awareness with health care policy makers that OA is the leading cause of disability in older adults. One of Canada’s leading osteoarthritis researchers, Dr. Gillian Hawker, Sir John and Lady Eaton Professor and Chair of Medicine, Faculty of Medicine, University of Toronto has stated: “the highest rates of OA are increasing fastest among young people (20-59 years), due largely to childhood obesity and knee injury. While effective therapies exist, the high prevalence of comorbidity in people with OA makes management challenging (as many of 90% of people with OA have at least one additional chronic condition – most often diabetes, heart disease and high blood pressure).”
Continue reading

ACR News 1 – October 21, 2018

newspaper in mail slotMore than 15,000 clinicians, researchers, academics, patient advocates and arthritis health professionals from more than 100 countries are expected to gather at the American College of Rheumatology/Association of Rheumatology Health Professionals 2018 Annual Meeting over the next six days in Chicago to exchange scientific and clinical information.

This year’s ACR/ARHP Annual Meeting will include 450 educational sessions. More than 700 speakers hailing from more than 20 countries will present as many as 3,000 abstracts to gain firsthand knowledge and access to new scientific and clinical findings.

Session topics will include newly proposed treatments for systemic lupus erythematosus and osteoarthritis, updated classification criteria for large vessel vasculitis and a look at current controversies regarding arthritis diseases and bone.
Continue reading

Rappel: Demande de rétroaction de patients sur le tofacitinib (Xeljanz®) pour le traitement de l’arthrite psoriasique

Megaphone GraphicSouffrez-vous d’arthrite psoriasique ou prodiguez-vous des soins à quelqu’un qui en souffre ? Vos commentaires seraient précieux.

Le Programme commun d’évaluation des médicaments (PCEM) accueille actuellement les commentaires et suggestions des patients et des fournisseurs de soins sur la présentation par le fabricant du tofacitinib (Xeljanz®) pour le traitement de l’arthrite psoriasique lorsque la réponse au traitement antérieur par un antirhumatismal modificateur de la maladie (ARMM) s’est avérée inadéquate.

Le PCEM fait partie de l’Agence canadienne des médicaments et des technologies de la santé. Le PCEM examine avec objectivité et rigueur l’efficacité et la rentabilité des médicaments et fournit des recommandations aux régimes d’assurance-médicaments publics du Canada (à l’exception du Québec) quant à leur inscription sur la liste des médicaments assurés.

Afin de l’aider dans son processus de recommandation, le PCEM accepte la rétroaction de groupe de patients comme le comité ACE (Arthritis Consumer Experts). C’est dans cette optique que nous désirons recueillir vos commentaires pour communication au PCEM.

Voici l’information que recherche le PCEM dans ce dossier particulier : Continue reading

Nous vous invitons à répondre à un sondage pour le développement d’un « outil d’information sur l’arthrose destiné aux patients »

Nous vous invitons à répondre à un sondage pour le développement d’un « outil d’information sur l’arthrose destiné aux patients »

L’outil d’information sur l’arthrose destiné aux patients sera une nouvelle ressource éducative et documentaire précieuse pour les personnes aux prises avec de l’arthrose, précoce ou bien établie, au niveau des mains, des genoux et (ou) de la hanche. 

L’Alliance de l’arthrite du Canada, le Collège des médecins de famille du Canada et le Centre for Effective Practice sollicitent votre collaboration afin de contribuer au développement d’une nouvelle ressource éducative et documentaire qui sera précieuse pour les personnes aux prises avec de l’arthrose, précoce ou bien établie, au niveau des mains, des genoux et (ou) de la hanche. Cet outil d’information aidera les patients atteints d’arthrose à avoir des discussions plus efficaces avec leur médecin ou autres professionnels de la santé en les informant quant aux soins auxquels ils peuvent s’attendre.

Il vous faudra environ 10 minutes pour répondre au sondage. Votre participation demeurera anonyme. La date limite pour y répondre est le mercredi 25 juillet 2018 à 17 h, heure normale du Pacifique.

Merci de votre aide et de votre temps !

Cordialement,

Arthritis Consumer Experts

Please take the development survey for an “Osteoarthritis (OA) Information Tool for Patients”

The Osteoarthritis (OA) Information Tool for Patients will be a valuable information and education resource for people experiencing early or established hand, knee and/or hip OA.

The Arthritis Alliance of Canada, The College of Family Physicians of Canada and the Centre for Effective Practice need your help to inform the development of a new and valuable information and education resource for people experiencing early or established hand, knee and/or hip osteoarthritis. The Osteoarthritis (OA) Information Tool for Patients will assist patients in having better conversations with their doctor or other health care professional(s) by informing them about the care they can expect to receive.

The survey will take approximately 10 minutes to complete. Your participation will be anonymous. The deadline to complete the survey is Wednesday, July 25, 2018 at 5pm Pacific Standard Time.

Thank you for your time and help!

Sincerely,

Arthritis Consumer Experts

JointHealth™ insight – June 2018

JointHealth™ Education Advanced Therapies for Inflammatory Arthritis – “Knowledge is power!”

JointHealth insight title page
In Arthritis Consumer Experts’ (ACE) June JointHealth™ insight, they introduce their newest JointHealth™ education course, Advanced Therapies for Inflammatory Arthritis.

This edition of JointHealth™ insight covers the following topics:

  • The inspiration behind JointHealth™ education, and other courses offered through the program
  • Conventional and advanced therapies for inflammatory arthritis
  • The importance of understanding therapy choices
  • A lesson plan for JointHealth™ Education Advanced Therapies for Inflammatory Arthritis
  • A rheumatologist’s perspective on the new course
  • A patient “graduate’s” perspective on the new course
  • Other resources related to advanced medications and therapy changes in Canada

To sign up for the JointHealth™ Education Advanced Therapies for Inflammatory Arthritis course, please click here.

Demande de rétroaction de patients sur le tofacitinib (Xeljanz®) pour le traitement de l’arthrite psoriasique

Megaphone GraphicSouffrez-vous d’arthrite psoriasique ou prodiguez-vous des soins à quelqu’un qui en souffre ? Vos commentaires seraient précieux.

Le Programme commun d’évaluation des médicaments (PCEM) accueille actuellement les commentaires et suggestions des patients et des fournisseurs de soins sur la présentation par le fabricant du tofacitinib (Xeljanz®) pour le traitement de l’arthrite psoriasique lorsque la réponse au traitement antérieur par un antirhumatismal modificateur de la maladie (ARMM) s’est avérée inadéquate.

Le PCEM fait partie de l’Agence canadienne des médicaments et des technologies de la santé. Le PCEM examine avec objectivité et rigueur l’efficacité et la rentabilité des médicaments et fournit des recommandations aux régimes d’assurance-médicaments publics du Canada (à l’exception du Québec) quant à leur inscription sur la liste des médicaments assurés.

Afin de l’aider dans son processus de recommandation, le PCEM accepte la rétroaction de groupe de patients comme le comité ACE (Arthritis Consumer Experts). C’est dans cette optique que nous désirons recueillir vos commentaires pour communication au PCEM.

Voici l’information que recherche le PCEM dans ce dossier particulier : Continue reading

Call for patient input on tofacitinib (Xeljanz®) for psoriatic arthritis

Megaphone GraphicDo you have psoriatic arthritis or care for someone who does? We need your valuable input.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input on the manufacturer’s submission for tofacitinib (Xeljanz®) for the treatment of psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.

The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).

To help them make their recommendations, the CDR accepts input from patient groups, like Arthritis Consumer Experts (ACE). We would like to gather your views and share them with the CDR.

These are the questions they are asking: Continue reading